Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPT plus thalidomide in relapsed or refractory multiple myeloma
ChiCTR-ONC-12002066Phase 2Completed
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Dec 2009
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camptothecin and thalidomide in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Adverse events and Objective response rate. Started Dec 2009; status: completed.
02
Drugs
camptothecinthalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-ONC-12002066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002066.